RHEB and acute myeloid leukemia: Here, we convincingly showed that rapamycin could further enhance apoptosis in Rheb-deficient AML or LSC cells, suggesting the combinational use of Rheb1-specific inhibitors and improved rapalogs that better target mTORC1 might eradicate LSCs in AML patients with higher Rheb1 or mTORC1 levels.